These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 33444492)

  • 1. Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia.
    Joaqui VB; Gómez NB; Ortiz RC; Toro LMO; Lombo JPM; Cifuentes CAS; García MAM; Lomba AA
    Arch Endocrinol Metab; 2021 Nov; 65(1):49-59. PubMed ID: 33444492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
    Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
    Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
    Zhuang Y; Song J; Ying M; Li M
    Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety].
    Xu Y; Wu P; Wen W; Chen H
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Nov; 39(11):1305-1311. PubMed ID: 31852646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
    Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
    Shigiyama F; Kumashiro N; Miyagi M; Ikehara K; Kanda E; Uchino H; Hirose T
    Cardiovasc Diabetol; 2017 Jul; 16(1):84. PubMed ID: 28683796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
    Mathieu C; Herrera Marmolejo M; González González JG; Hansen L; Chen H; Johnsson E; Garcia-Sanchez R; Iqbal N
    Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
    Henry RR; Murray AV; Marmolejo MH; Hennicken D; Ptaszynska A; List JF
    Int J Clin Pract; 2012 May; 66(5):446-56. PubMed ID: 22413962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
    Jabbour SA; Frías JP; Ahmed A; Hardy E; Choi J; Sjöström CD; Guja C
    Diabetes Care; 2020 Oct; 43(10):2528-2536. PubMed ID: 32816874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
    Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
    Vilsbøll T; Ekholm E; Johnsson E; Garcia-Sanchez R; Dronamraju N; Jabbour SA; Lind M
    Diabetes Obes Metab; 2020 Jun; 22(6):957-968. PubMed ID: 32003150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.